NeuroSense Therapeutics Ltd NRSN

NAS: NRSN | ISIN: IL0011809592   20/07/2026
0,690 USD (+0,80%)
(+0,80%)   20/07/2026

6 juli 2026 · NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" · Persbericht

29 juni 2026 · NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS · Persbericht

25 juni 2026 · NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease · Persbericht

22 juni 2026 · EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots · Persbericht

11 juni 2026 · NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS · Persbericht

9 juni 2026 · NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition · Persbericht

28 april 2026 · NeuroSense Announces Pricing of Insider-Led PIPE Financing · Persbericht

6 april 2026 · NeuroSense Granted Brazilian Patent Covering PrimeC Composition · Persbericht

3 april 2026 · NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements · Persbericht

31 maart 2026 · NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update · Persbericht

24 maart 2026 · NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout · Persbericht

18 maart 2026 · /C O R R E C T I O N -- NeuroSense/ · Persbericht

18 maart 2026 · PrimeC New Data to Be Presented at AD/PD™ 2026 Conference · Persbericht

16 maart 2026 · JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity · Persbericht

9 maart 2026 · PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference · Persbericht

18 februari 2026 · NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS · Persbericht

9 februari 2026 · NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition · Persbericht

21 januari 2026 · NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease · Persbericht

8 januari 2026 · World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB · Persbericht

22 december 2025 · NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study · Persbericht

Mijn selecties